Clinical Trial

AI-Enhanced Optimization of Acute Levodopa Challenge Test

Recruiting
View on ClinicalTrials.gov →
Summary
A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence. Combined with traditional motor paradigms and the acute levodopa challenge test, this study aims to identify diagnostic cut-off values for PD and other atypical parkinonism, explore digital biomarkers for early and differential diagnosis, and establish a corresponding diagnostic model.
Trial Details
NCT Number NCT06949865
Lead Sponsor Beijing Tiantan Hospital
Collaborators: Ruijin Hospital, Nanjing Medical University, Second Affiliated Hospital of Soochow University, Beijing Hospital, Fujian Medical University Union Hospital, Guangdong Provincial People's Hospital, West China Hospital, The First Affiliated Hospital of Dalian Medical University, China-Japan Union Hospital, Jilin University, Renmin Hospital of Wuhan University, First Affiliated Hospital of Chongqing Medical University, Second Affiliated Hospital of Nanchang University, Xijing Hospital, The Affiliated Hospital of Qingdao University, The Second Affiliated Hospital of Xinjiang Medical University, Shenzhen People's Hospital, Tianjin Medical University General Hospital, Qilu Hospital of Shandong University, The First People's Hospital of Yunnan, The First Hospital of Jilin University, Tianjin Huanhu Hospital, The First Affiliated Hospital of Anhui Medical University, Wannan Medical College Yijishan Hospital, The Affiliated Hospital of Xuzhou Medical University
Conditions Vascular Parkinsonism, Drug-induced Parkinsonism, Corticobasal Degeneration (CBD), Parkinson Disease (PD), Dementia With Lewy Body Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy (MSA)
Enrollment 2,000 participants
Start Date 2024-05-28
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-29